Cite
1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS
MLA
G.T. Everson, et al. “1399 12-Week Interferon-Free Regimen of Abt-450/R +Abt-333 +Ribavirin Achieved Svr12 in More Than 90% of Treatment-Naive Hcv Genotype-1-Infected Subjects and 47% of Previous Non-Responders.” Journal of Hepatology, vol. 56, Apr. 2012, pp. S549–50. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........71dd18358ab4fde32991578a535952f0&authtype=sso&custid=ns315887.
APA
G.T. Everson, B. Bernstein, M. Heckaman, T. Pilot Matias, Fred Poordad, D. Cohen, R. Menon, S. Siggelkow, B. Freilich, Kris V. Kowdley, T. Podsadecki, & E.J. Lawitz. (2012). 1399 12-Week Interferon-Free Regimen of Abt-450/R +Abt-333 +Ribavirin Achieved Svr12 in More Than 90% of Treatment-Naive Hcv Genotype-1-Infected Subjects and 47% of Previous Non-Responders. Journal of Hepatology, 56, S549–S550.
Chicago
G.T. Everson, B. Bernstein, M. Heckaman, T. Pilot Matias, Fred Poordad, D. Cohen, R. Menon, et al. 2012. “1399 12-Week Interferon-Free Regimen of Abt-450/R +Abt-333 +Ribavirin Achieved Svr12 in More Than 90% of Treatment-Naive Hcv Genotype-1-Infected Subjects and 47% of Previous Non-Responders.” Journal of Hepatology 56 (April): S549–50. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........71dd18358ab4fde32991578a535952f0&authtype=sso&custid=ns315887.